CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study Journal Article

  

Authors:	Gardner, G. J.; Baser, R. E.; Brady, M. F.; Bristow, R. E.; Markman, M.; Spriggs, D.; Thaler, H. T.
Article Title:	CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study
Abstract:	Objective: CA125 is a non-specific marker of peritoneal irritation which has the potential for false elevation during intraperitoneal treatment. The purpose of this study is to identify the rate of CA125 regression during intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer. Methods: GOG 114, a randomized control trial evaluating IP and IV treatment, includes an intensive CA125 measurement schema with weekly CA125 levels until ≤ 35 units/ml for both IP- and IV-treated patients. Rate of CA125 normalization, median CA125 values for each treatment cycle, as well as clinical and pathologic features were compared between the treatment groups. Baseline CA125 levels and rate of CA125 decline were evaluated with respect to overall survival. Results: CA125 data were available for 223 patients who received IV cisplatin/paclitaxel and for 231 patients who received IV carboplatin followed by IP cisplatin/paclitaxel. Standard prognostic criteria and baseline CA125 values were similar between the treatment groups. For treatment cycles in which IP-treatment was administered, there was no statistically significant difference in CA125 levels between IV- and IP-treated patients. The rate of CA125 normalization was similar between IV- and IP-treated patients (p = 0.55). Patients with low pre-chemotherapy CA125 levels which rapidly declined during treatment demonstrated a survival advantage (p < 0.0001). Conclusions: No difference in CA125 decline was identified between IP- and IV-treated patients undergoing a weekly CA125 monitoring schedule. This data supports the utilization of standard CA125 response criteria in the therapeutic monitoring for patients receiving IP treatment. © 2011 Elsevier Inc. All rights reserved.
Keywords:	adolescent; adult; cancer survival; controlled study; aged; aged, 80 and over; middle aged; young adult; major clinical study; overall survival; cisplatin; cancer combination chemotherapy; conference paper; paclitaxel; ovarian cancer; ovarian neoplasms; carboplatin; multiple cycle treatment; ovary cancer; randomized controlled trial; antineoplastic combined chemotherapy protocols; drug administration schedule; membrane proteins; cyclophosphamide; patient monitoring; oncology; cancer regression; ca 125 antigen; ca-125 antigen; infusions, intravenous; infusions, parenteral; platinum-based chemotherapy; gog; ca125 regression
Journal Title:	Gynecologic Oncology
Volume:	124
Issue:	2
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2012-02-01
Start Page:	216
End Page:	220
Language:	English
DOI:	10.1016/j.ygyno.2011.10.021
PROVIDER:	scopus
PUBMED:	22033034
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84855987221&partnerID=40&md5=84044e4d1ebafa500e6f5439fb4e5109
Notes:	--- - "Export Date: 1 March 2012" - "CODEN: GYNOA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/23534